Breast Cancer
Conference Coverage
Novel SERD, LSZ102, shows promise for pretreated ER+ breast cancer
LSZ102 was relatively well tolerated as a single agent and in combination with ribociclib and alperisib.
News from the FDA/CDC
FDA approves in-home breast cancer treatment
From the Journals
Cardiology care ups CV monitoring, BP control in HER2+ breast cancer
From the Journals
American Cancer Society update: ‘It is best not to drink alcohol’
Conference Coverage
Germline testing in advanced cancer can lead to targeted treatment
In a study of nearly 12,000 cancer patients, 7%-9% of patients had targetable germline alterations.
Conference Coverage
Treating primary tumor doesn’t improve OS in stage IV breast cancer
Conference Coverage
Pyrotinib bests lapatinib in HER2+ metastatic breast cancer
Patients who received pyrotinib had longer progression-free survival but a higher rate of grade 3 diarrhea.
Conference Coverage
Expanding the role of PARP inhibitors in breast cancer
Conference Coverage
ALTERNATE trial: No fulvestrant benefit in locally advanced ER+ HER2– breast cancer
The endocrine-sensitive disease rate was similar whether patients received anastrozole alone, fulvestrant alone, or fulvestrant plus anastrozole...
Conference Coverage
Tucatinib improves PFS, OS in HER2+ breast cancer with brain metastases
Conference Coverage
TRAIN-2: Anthracyclines added toxicity, with no increased efficacy, in HER2+ breast cancer